Equities

West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)316.59
  • Today's Change-4.29 / -1.34%
  • Shares traded578.00
  • 1 Year change-9.85%
  • Beta1.0005
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

  • Revenue in USD (TTM)2.88bn
  • Net income in USD499.60m
  • Incorporated1923
  • Employees10.60k
  • Location
    West Pharmaceutical Services Inc530 Herman O. West DriveEXTON 19341United StatesUSA
  • Phone+1 (610) 594-2900
  • Fax+1 (800) 345-9800
  • Websitehttps://www.westpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Globus Medical Inc2.48bn91.51m13.44bn5.00k127.662.8338.415.420.66360.663618.0829.940.47471.284.58495,719.201.756.901.997.4558.1471.733.6914.051.64--0.09740.0053.3417.08-35.39-4.725.57--
Revvity Inc2.72bn258.26m13.63bn11.50k53.481.7319.865.012.092.0622.0664.880.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9711.960.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.82bn309.60m14.14bn14.50k45.732.5519.792.070.45440.454410.018.160.5325.566.09470,331.002.422.972.753.3533.5333.444.545.061.063.290.46980.00-7.263.51-51.52--31.17--
Align Technology, Inc.3.96bn441.57m16.86bn21.61k38.504.2828.964.265.875.8752.6352.760.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14--0.000.003.4214.4523.092.15-4.46--
Baxter International Inc11.77bn225.00m16.94bn60.00k75.132.1512.921.440.4420.21423.1015.420.41052.915.42196,133.300.81980.19421.050.233338.4338.202.000.36741.093.810.61961,398.942.125.9497.15--0.9829.71
Hologic Inc4.03bn789.50m18.34bn6.99k23.783.5816.704.553.323.3216.9722.090.44062.726.57--8.6313.129.8415.2056.2560.8219.5924.753.0364.450.3307---0.00253.6673.14--4.30--
Insulet Corp1.98bn420.90m18.44bn3.00k45.7116.5036.969.305.755.7525.9615.940.72231.426.14661,300.0015.322.7118.563.1469.3665.8121.224.282.8098.710.55570.0030.0224.664,384.78128.77-7.63--
Cooper Companies Inc3.80bn359.30m20.07bn15.00k56.132.5327.275.281.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Steris PLC5.12bn602.62m21.16bn18.18k35.283.2119.104.136.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Zimmer Biomet Holdings Inc7.60bn1.08bn21.94bn18.00k20.991.7810.662.895.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
Waters Corp2.91bn622.64m22.18bn7.90k35.6313.8327.227.6310.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Illumina Inc4.39bn-1.58bn22.23bn10.59k--10.49--5.06-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
West Pharmaceutical Services Inc.2.88bn499.60m22.93bn10.60k46.918.3436.157.976.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
DexCom Inc3.95bn680.80m28.45bn9.60k44.4614.3731.857.191.641.649.525.070.61072.764.42411,875.0010.518.3014.2810.5062.1065.9017.2214.142.12--0.55790.0024.4928.5658.70--28.66--
Data as of Nov 22 2024. Currency figures normalised to West Pharmaceutical Services Inc's reporting currency: US Dollar USD

Institutional shareholders

45.57%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20248.66m11.96%
BlackRock Fund Advisorsas of 30 Sep 20244.18m5.77%
SSgA Funds Management, Inc.as of 30 Sep 20243.21m4.44%
Artisan Partners LPas of 30 Sep 20243.07m4.23%
Walter Scott & Partners Ltd.as of 30 Sep 20242.76m3.81%
AllianceBernstein LPas of 30 Sep 20242.60m3.60%
APG Asset Management NVas of 30 Sep 20242.31m3.19%
Franklin Advisers, Inc.as of 30 Sep 20242.26m3.11%
Brown Advisory LLCas of 30 Sep 20242.22m3.06%
Geode Capital Management LLCas of 30 Sep 20241.74m2.40%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.